RemeGen CoFRA:REG -2.42%39 Net Debt Paydown Yield % is 0.04% as of Jul. 11, 2026. GuruFocus rates FRA:REG with a GF Score™ of 39/100 and a GF Value™ of €21.08 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,159 Biotechnology companies, RemeGen Co ranks better than 51.25% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, RemeGen Co's Net Debt Paydown Yield % was 0.04%.
RemeGen Co (FRA:REG) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
RemeGen Co Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:REG vs VRTX, REGN, ALNY: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, RemeGen Co's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.04% mean?
RemeGen Co (FRA:REG) has a Net Debt Paydown Yield % of 0.04% as of Jul. 11, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #565 out of 1159 companies in the Biotechnology industry, placing it in the top 48.7%.
Is RemeGen Co's Net Debt Paydown Yield % too high?
RemeGen Co's current Net Debt Paydown Yield % is 0.04%. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. RemeGen Co's value of 0.04% is 33.3% above this industry median. Based on the distribution chart, RemeGen Co ranks #565 out of 1159 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RemeGen Co has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Net Debt Paydown Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #565 out of 1159 companies for Net Debt Paydown Yield %. This puts RemeGen Co in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.03. RemeGen Co's value of 0.04% is 33.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Net Debt Paydown Yield % of 0.04% is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Net Debt Paydown Yield % is 0.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €21.08, compared to a current price of €9.36 — trading 55.6% below its estimated fair value. The current Net Debt Paydown Yield % is 0.04% and 33.3% above the Biotechnology industry median of 0.03. RemeGen Co's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Net Debt Paydown Yield % is 0.04% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €9.36 is trading 55.6% below its estimated GF Value™ of €21.08.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Net Debt Paydown Yield %: 0.04%
GF Value™: €21.08 vs. price of €9.36 (55.6% below fair value)
Industry Position: 33.3% above the Biotechnology median (#565 of 1159)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
39GF Score
Get the complete analysis for FRA:REG
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
